Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies.
Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies.
复制标题
DOI：
10.18632/oncotarget.8203
复制
发表时间：
2016-07-12
期刊：
影响因子：
--
通讯作者：
Suh KS
中科院分区：
文献类型：
--
作者：
Akl MR;Nagpal P;Ayoub NM;Tai B;Prabhu SA;Capac CM;Gliksman M;Goy A;Suh KS
成纤维细胞生长因子（FGF）信号传导对于正常和癌症生物学是必不可少的。哺乳动物FGF家族成员通过以不同的亲和力与硫酸乙酰肝素和FGF受体（FGFR）结合参与多种信号传导途径。FGF 2是FGF家族的原型成员，并与其受体相互作用以介导受体二聚化、磷酸化和信号传导途径如Ras-MAPK和PI 3 K途径的活化。通过FGF/FGFR轴的过度促有丝分裂信号传导可能通过促进癌症进展和增加血管生成潜力而诱导致癌作用，这可能导致转移性肿瘤表型。FGF/FGFR信号转导失调与侵袭性癌症表型、增强的化疗耐药性和不良临床结局相关。体外实验环境表明，细胞外FGF 2影响癌细胞的增殖、药物敏感性和凋亡。靶向FGF 2和FGFR的治疗已在多项临床前研究中进行了广泛评估，许多药物和治疗方案已在临床试验中进行了测试。诊断测定用于定量FGF 2、FGFR和下游信号传导分子，以更好地选择目标患者群体以获得更高的癌症治疗功效。本文综述了FGF 2在肿瘤中的预后意义，重点是实体瘤和血液系统恶性肿瘤的治疗干预策略。
Fibroblast growth factor (FGF) signaling is essential for normal and cancer biology. Mammalian FGF family members participate in multiple signaling pathways by binding to heparan sulfate and FGF receptors (FGFR) with varying affinities. FGF2 is the prototype member of the FGF family and interacts with its receptor to mediate receptor dimerization, phosphorylation, and activation of signaling pathways, such as Ras-MAPK and PI3K pathways. Excessive mitogenic signaling through the FGF/FGFR axis may induce carcinogenic effects by promoting cancer progression and increasing the angiogenic potential, which can lead to metastatic tumor phenotypes. Dysregulated FGF/FGFR signaling is associated with aggressive cancer phenotypes, enhanced chemotherapy resistance and poor clinical outcomes. In vitro experimental settings have indicated that extracellular FGF2 affects proliferation, drug sensitivity, and apoptosis of cancer cells. Therapeutically targeting FGF2 and FGFR has been extensively assessed in multiple preclinical studies and numerous drugs and treatment options have been tested in clinical trials. Diagnostic assays are used to quantify FGF2, FGFRs, and downstream signaling molecules to better select a target patient population for higher efficacy of cancer therapies. This review focuses on the prognostic significance of FGF2 in cancer with emphasis on therapeutic intervention strategies for solid and hematological malignancies.
登录
查看更多内容
影响因子：
50.3
作者：
Casanovas, O;Hicklin, DJ;Hanahan, D
通讯作者：
Hanahan, D
影响因子：
11.2
作者：
Chaffer, Christine L.;Brennan, Janelle P.;Williams, Elizabeth D.
通讯作者：
Williams, Elizabeth D.
影响因子：
11.5
作者：
Angevin, Eric;Lopez-Martin, Jose A.;Escudier, Bernard
通讯作者：
Escudier, Bernard
影响因子：
20.3
作者：
BERARDI, AC;WANG, AL;SCADDEN, DT
通讯作者：
SCADDEN, DT
影响因子：
3.7
作者：
Cao XC;Zhang WR;Cao WF;Liu BW;Zhang F;Zhao HM;Meng R;Zhang L;Niu RF;Hao XS;Zhang B
通讯作者：
Zhang B